bersanlimab (BI-505) / BioInvent - LARVOL DELTA

Bioinformatics analysis of key genes and potential therapeutic agents for vascular calcification in chronic kidney disease. (PubMed, Nucleosides Nucleotides Nucleic Acids) - "Most notably, the top five potential therapeutic drugs-ENAVATUZUMAB, DENOSUMAB, ALICAFORSEN, BI-505, and ENLIMOMAB PEGOL-were identified for vascular calcification in CKD. However, further molecular biological experiments are required to confirm these findings."

Journal • Chronic Kidney Disease • Nephrology • Renal Disease • ICAM1 • TNFRSF11A • TNFRSF12A • TNFRSF25 • TNFSF11

A novel topoisomerase I inhibitor based anti-ICAM‑1 antibody drug conjugate for the treatment of hematologic malignancies and solid tumors (AACR 2023) - "Previous attempt to target ICAM‑1 with a monoclonal antibody bersanlimab (BI505, BioInvent) showed that it was well-tolerated but with limited clinical efficacy...Furthermore, in a repeat dose exploratory non-human primate safety study, the benchmark conjugate ICAM‑1‑DXd (DAR 8) was well-tolerated at 41 mg/kg, the highest dose tested. In conclusion, ICAM‑1 is an attractive target for topoisomerase I inhibitor based ADC and warrants further investigation."

Gastrointestinal Cancer • Hematological Malignancies • Liver Cancer • Lung Cancer • Lymphoma • Melanoma • Multiple Myeloma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ICAM1

Multiple modes of action of the CD38 x ICAM-1 bispecific antibody (AACR 2022) - "Antibody against ICAM-1, bersanlimab (BI505, BioInvent), was well-tolerated, but only showed limited clinical efficacy in MM patients. Most importantly, the CD38 x ICAM1 bispecific antibody demonstrated potent tumor inhibition activities in in-vivo myeloma and lymphoma models. These studies suggested that CD38 x ICAM-1 bispecific antibody has multiple modes of action for treating lymphoma and multiple myeloma."

IO biomarker • Hematological Malignancies • Lymphoma • Multiple Myeloma • Oncology • Solid Tumor • ICAM1

CD38 x ICAM1 Bispecific Antibody Is a Novel Approach for Treating Multiple Myeloma and Lymphoma (ASH 2021) - "Antibody against ICAM1, bersanlimab (BI505, BioInvent), was well-tolerated, but only showed limited clinical efficacy in MM patients. Most importantly, the CD38 x ICAM1 bispecific antibody showed complete tumor inhibition in a rituximab-resistant lymphoma PDX model, whereas daratumumab only showed minimal efficacy. In conclusion, the CD38 x ICAM1 bispecific antibody demonstrated improved efficacy and specificity toward CD38 + and ICAM1 + tumor cells and represents a novel approach for treating multiple myeloma and lymphoma."

IO biomarker • Hematological Malignancies • Inflammatory Arthritis • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • ICAM1

A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma (clinicaltrials.gov) - P1; N=35; Completed; Sponsor: BioInvent International AB; Active, not recruiting ➔ Completed

Clinical • Trial completion

Emerging immune targets for the treatment of multiple myeloma. (PubMed, Immunotherapy) - "...Other monoclonal antibodies that have shown efficacy in combination therapy include siltuximab (OR: 66%), indatuximab (OR: 78%), isatuximab (OR: 64.5%), pembrolizumab (OR: 60%), bevacizumab (OR: 70%), dacetuzumab (OR: 39%) and lorvotuzumab (OR: 56.4%). No OR was observed with monotherapy using BI-505, siltuximab, bevacizumab, AVE-1642, figitumumab, atacicept, milatuzumab, dacetuzumab, lucatumumab, IPH2101, lorvotuzumab, BT062 and nivolumab...A recent experience of CAR T-cell (B-cell maturation antigen) therapy in advanced MM has shown global response of 100%. The future of monoclonal antibodies and adoptive T cells for MM treatment seems promising."

Journal